Penile and urethral cancers are rare but treatable if detected early. Know the subtle warning signs, risk factors, and why ...
Executives from Oric Pharmaceuticals (NASDAQ:ORIC) used a conference discussion to highlight near-term clinical catalysts for ...
At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.
There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...
Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...
New AI tool from UC San Diego and collaborators precisely maps the urethra on MRI to make prostate cancer radiation safer and reduce urinary side effects. Running on SDSC’s Expanse supercomputer, the ...
Oncology Media Relations oncology_media_relations@its.jnj.com Investor contact: Jessica Margevich investor-relations@its.jnj.com ...
In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...
Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
3d
Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, study finds
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to ...
Investing.com - Bayer AG filed a lawsuit Monday in New York federal court accusing Johnson & Johnson of making false and misleading claims in advertisements for its prostate cancer drug Erleada, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results